<DOC>
	<DOCNO>NCT00415064</DOCNO>
	<brief_summary>This phase I study perifosine combination lenalidomide dexamethasone patient relapse refractory multiple myeloma . The current protocol enroll patient relapse refractory multiple myeloma require second third line therapy . Six patient treat one 4 dose level phase 1 study . All patient receive perifosine , lenalidomide dexamethasone 28 day cycle . The dos perifosine lenalidomide vary group . The dose dexamethasone remain constant .</brief_summary>
	<brief_title>Phase I Study Perifosine + Lenalidomide Dexamethasone Patients With Multiple Myeloma</brief_title>
	<detailed_description>This phase I study perifosine combination lenalidomide dexamethasone patient relapse refractory multiple myeloma . All patient receive lenalidomide daily day 1 21 28 day cycle . Perifosine give daily qhs food . Dexamethasone give day 1-4 , 9-12 17-20 4 cycle . After 4 cycle dexamethasone give day 1-4 . Four dose level study : 1 . Perifosine 50 mg , lenalidomide 15 mg dexamethasone 20 mg 2 . Perifosine 50 mg , lenalidomide 25 mg dexamethasone 20 mg 3 . Perifosine 100 mg , lenalidomide 15 mg dexamethasone 20 mg 4 . Perifosine 100 mg , lenalidomide 25 mg dexamethasone 20 mg Six patient enrol dose level maximum tolerate dose ( MTD ) reach . Six additional patient treat MTD .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Subject previously diagnose multiple myeloma base standard diagnostic criterion , follow . Major criterion : 1 . Plasmacytomas tissue biopsy . 2 . Bone marrow plasmacytosis ( &gt; 30 % plasma cell ) . 3 . Monoclonal immunoglobulin spike serum electrophoresis immunoglobulin G ( IgG ) &gt; 3.5 g/dL immunoglobulin A ( IgA ) &gt; 2.0 g/dL ; kappa lambda light chain excretion &gt; 1 g/day 24 hour urine protein electrophoresis . Patients must relapse refractory disease ( refractory define progression treatment within 60 day completion treatment ) require 2nd 3rd line therapy Patients refractory combination lenalidomide dexamethasone eligible . Patients may receive lenalidomide and/or dexamethasone Renal insufficiency ( serum creatinine level &gt; 3 mg/dL ) .. History allergic reaction attribute compound similar chemical biologic composition perifosine ( miltefosine edelfosine ) . Known hypersensitivity thalidomide</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Perifosine</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>Dexamethasone</keyword>
</DOC>